BSEM (BioStem Technologies) Scaled Net Operating Assets: 0.19 (As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.59
GF Value $139.96
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Scaled Net Operating Assets?

BioStem Technologies BSEM +4.22% 49 Scaled Net Operating Assets is 0.19 as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BioStem Technologies's operating assets for the quarter that ended in Sep. 2025 was $35.2 Mil. BioStem Technologies's operating liabilities for the quarter that ended in Sep. 2025 was $9.0 Mil. BioStem Technologies's Total Assets for the quarter that ended in Dec. 2024 was $140.4 Mil. Therefore, BioStem Technologies's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2025 was 0.19.

BioStem Technologies Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Scaled Net Operating Assets Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.49 0.14 0.91 1.54

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.54 0.87 0.22 0.19

BSEM vs TCRX, BYSI, MCRB: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, BioStem Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Scaled Net Operating Assets falls into.


BSEM
49GF Score
BioStem Technologies Inc BSEM
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BioStem Technologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(117.543-95.106)/14.56
=1.54

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=140.376 - 22.833
=117.543

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=99.5 - 0.33 - 4.064
=95.106

BioStem Technologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2025 )
=(Operating Assets (Q: Sep. 2025 )-Operating Liabilities (Q: Sep. 2025 ))/Total Assets (Q: Dec. 2024 )
=(35.235-8.989)/140.376
=0.19

where

Operating Assets(Q: Sep. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=62.393 - 27.158
=35.235

Operating Liabilities(Q: Sep. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=12.376 - 0.158 - 3.229
=8.989

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.19 mean?
BioStem Technologies (BSEM) has a Scaled Net Operating Assets of 0.19 as of Sep. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' Scaled Net Operating Assets too high?
BioStem Technologies' current Scaled Net Operating Assets is 0.19. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Scaled Net Operating Assets compare to TCRX and BYSI?
BioStem Technologies' Scaled Net Operating Assets of 0.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Scaled Net Operating Assets is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.59 — trading 97.4% below its estimated fair value. The current Scaled Net Operating Assets is 0.19. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Scaled Net Operating Assets is 0.19 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.59 is trading 97.4% below its estimated GF Value™ of $139.96. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • Scaled Net Operating Assets: 0.19
  • GF Value™: $139.96 vs. price of $3.59 (97.4% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$139.96
GF Value